TABLE 2.
Organ Involvement by Clinical Symptoms and by Visual and Quantitative Uptake of 18F-Florbetapir in Various Organs in Systemic AL Amyloidosis
| SUVmax in subjects with… |
|||||
| Organ involved | Clinical diagnosis | Visual analysis | Quantitative analysis | Involved organs | Uninvolved organs |
| Parotid | 1 (3%) | 20 (50%) | 19 (48%) | 3.9 ± 1.4 | 1.5 ± 0.5 |
| Tongue | 4 (10%) | 17 (43%) | 21 (53%) | 3.9 ± 1.1 | 1.8 ± 0.3 |
| Thyroid | — | 9 (23%) | 14 (36%) | 6.5 ± 6.3 | 1.5 ± 0.5 |
| Lung | 4 (10%) | 11 (28%) | 14 (35%) | 5.7 ± 3.3 | 1.0 ± 0.6 |
| Gastric wall | 1 (3%) | 13 (33%) | 15 (38%) | 5.4 ± 3.1 | 1.8 ± 0.4 |
| Pancreas | — | 5 (13%) | 16 (40%) | 3.1 ± 0.5 | 1.9 ± 0.5 |
| Kidney | 11 (28%) | 4 (10%) | 5 (13%) | 3.4 ± 0.5 | 1.9 ± 0.3 |
| Spleen | — | 8 (20%) | 8 (20%) | 6.7 ± 2.4 | 1.8 ± 0.4 |
| Gluteal muscle | — | 1 (3%) | 3 (8%) | 3.1 ± 0.2 | 1.3 ± 0.3 |
| Abdominal wall fat | 5 (13%) | 4 (10%) | 3 (8%) | 3.1 ± 0.3 | 1.1 ± 0.4 |
| Humeral head | 8 (20%) | 8 (2%) | 6 (15%) | 3.2 ± 0.7 | 1.4 ± 0.6 |
Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as mean ± SD. Involved organs are defined as having a SUVmax ≥ 2.5. Liver was considered unevaluable because of known hepatobiliary excretion of 18F-florbetapir. Heart was not evaluated because it comprised study inclusion criteria. Some organs do not have consensus criteria for clinical diagnosis.